Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sodimu, Adetoun, Bartolome, Sonja, Igenoza, Oluwatosin P., Chin, Kelly M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691907/
https://www.ncbi.nlm.nih.gov/pubmed/33282204
http://dx.doi.org/10.1177/2045894020971954
Descripción
Sumario:In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints.

Ejemplares similares